A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates-Reference-Cited by-同舟云学术

A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates

Published:2021-03-01 Issue:3 Volume:320 Page:H1124-H1135
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Shimatani Kenichiro¹,Sato Hiromu¹,Saito Atsuhiro²,Sasai Masao²,Watanabe Kenichi²,Mizukami Kazuhiko¹,Kamohara Masazumi¹,Miyagawa Shigeru²,Sawa Yoshiki²^ORCID

Affiliation:

1. Drug Discovery Research, Astellas Pharma Incorporated, Ibaraki, Japan

2. Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Abstract

We developed a chronic and severe hindlimb ischemia (HLI) mouse model for preclinical research on critical limb ischemia (CLI). This model partially reflects human CLI pathology in that it does not show spontaneous restoration of blood flow or expression of angiogenic genes in the ischemic limb. This novel model may be valuable for therapeutic evaluation of the angiogenic effects of CLI drug candidates.

Funder

Astellas Pharma Inc.

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00470.2020

Reference39 articles.

1. Critical limb ischemia: current challenges and future prospects

2. Critical Limb Ischemia: Current Trends and Future Directions

3. Open bypass and endoluminal therapy: complementary techniques for revascularization in diabetic patients with critical limb ischaemia